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Phospholipid-based nanocarriers are attractive drug carriers for improved local skin therapy. 
In the present study, the recently developed isolated perfused human skin flap (IPHSF) model 
was used to directly compare the skin penetration enhancing potential of the three commonly 
used nanocarriers, namely conventional liposomes (CLs), deformable liposomes (DLs) and 
solid lipid nanoparticles (SLNs). Two fluorescent markers, calcein (hydrophilic) or rhodamine 
(lipophilic), were incorporated individually in the three nanosystems. The nanocarrier size 
ranged between 200 and 300 nm; the surface charge and entrapment efficiency for both 
markers were dependent on the lipid composition and the employed surfactant. Both carrier-
associated markers could not penetrate the full thickness human skin, confirming their 
suitability for dermal drug delivery. CLs exhibited higher retention of both markers on the 
skin surface compared to DLs and SLNs, indicating a depo formation. DLs and SLNs enabled 
the deeper penetration of the two markers into the skin layers. In vitro and ex vivo skin 
penetration studies performed on the cellophane membrane and full thickness pig/human skin, 
respectively, confirmed the findings. In conclusion, efficient dermal drug delivery can be 
achieved by the optimization of a lipid nanocarrier on the suitable skin-mimicking model to 
assure system’s accumulation in the targeted skin layer. 
 
Keywords: local skin therapy; phospholipid-based nanosystems; skin penetration; human 
skin; liposomes; isolated perfused human flap. 
 
Abbreviations: CLs, conventional liposomes; CLSM, confocal laser scanner microscopy; 
DLs, deformable liposomes; IPHSF, isolated perfused human skin flap; IR, infrared; KHb, 
modified Krebs-Henseleit buffer; PC, phosphatidylcholine; PG, propylene glycol; PI, 
3 
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According to the Global Burden of Disease Study 2010, the skin diseases are the fourth 
leading cause of disease burden at global level. The skin-related illnesses are cause of the 
disability affecting between 30 and 70% of individuals [1]. Despite progress achieved in the 
local skin therapy, the treatment of skin diseases remains challenging [2]. Topical drug 
delivery for localized skin therapy bears some advantages compared to the traditional 
administration routes, such as the avoidance of systemic administration, the lower dose of 
drug required to reach the desired level at the targeted site and the reduction of systemic side 
effects [3]. In addition, an increase in the antimicrobial resistance among the drugs used to 
treat skin infections systemically, is emphasising the need for an efficient localized 
antimicrobial skin therapy [4]. However, the penetration of drugs into the deeper skin layers, 
especially through the stratum corneum (SC), remains an important challenge in the 
development of effective topical formulations destined to exert localized effect in the skin [5]. 
For example, in the inflammatory skin diseases (e.g. dermatitis, psoriasis) and fungal skin 
infections, leucocytes invade the skin leading to an increase in the proliferation and 
differentiation of keratinocytes and consequent increase in the skin thickness and further 
enhancement of the skin barrier properties exerted mainly by the SC [6]. The formulations 
that fail to achieve the optimal therapeutic drug levels within the deeper skin layers, or to 
assure the depot at the skin surface, are considered suboptimal. Among the emerging 
approaches employed to improve the dermal delivery of drugs, nanodermatology represents 
one of the most promising [7,8]. Nanocarriers have shown to improve the solubility of highly 
hydrophobic drugs, increase drug chemical and physical stability, deliver higher concentration 
of drugs to the targeted site and provide sustained and controlled release of the associated 
drugs [9]. Phospholipid-based nanosystems are of a particular interest and have been widely 
investigated for improving the topical skin therapy. Their phospholipid nature contributes to 
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low toxicity and high compatibility with physiological skin lipids, especially in the SC [10]. 
These lipid-based nanocarriers have shown to enhance the penetration through the skin by 
overcoming the intact skin barrier and allowing dermal delivery of associated drugs [11]. One 
of the first proposed vesicular nanosystems were the conventional liposomes (CLs). Their 
structure permits the incorporation of lipophilic, hydrophilic and amphiphilic compounds 
[12]. The similarities between CLs and skin lipids allow their accumulation on the SC surface 
and fusion with skin lipids. This induces changes in the SC intercellular lipids, thus increasing 
the skin permeability and drug penetration [10]. However, most of the literature proves that 
CLs remain mainly confined to the SC thus building a reservoir to release slowly release the 
associated drug. To improve drug penetration deeper into the skin layers, deformable 
liposomes (DLs) were proposed by Cevc and Blume [13]. These liposomes are composed of 
lipids and an edge activator, which provides elasticity and deformability to the liposomes. 
Consequently, DLs could potentially squeeze through the SC thus increasing the transport of 
the drug deeper into the skin layers [14].  
Alternative to liposomes are particulate lipid-based nanosystems, such as solid lipid 
nanoparticles (SLNs). SNLs are composed of one or more solid lipids dispersed in an aqueous 
medium with an addition, if necessary, of a surfactant as a stabiliser [15]. These nanocarriers 
lack the bilayer structure of the liposomes, thus being more stable in both hydrophilic and 
lipophilic environment [16]. SLNs allow controlled release of the drug and penetration 
enhancement exerted by their occlusive properties [17]. Furthermore, they exhibit good skin 
tolerability, and are considered to be safe and biocompatible [18].  
The lipid composition of the lipid-based nanocarriers is strongly influencing their 
physicochemical characteristics, such as particle size, surface charge, bilayer elasticity and 
thermodynamic phase. By optimizing the lipid composition, it is possible to 
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influence/optimize vesicle deposition onto/within the skin and modulate the depth to which 
the drug will be delivered [19].  
For the first time, we directly compared the skin penetration enhancement of three different 
lipid-based nanocarriers on the isolated human skin flap (IPHSF) model, a recently developed 
human skin perfusion model [20]. To follow the drug penetration from different lipid-based 
nanocarriers, two fluorescent markers with different lipophilicities, calcein and rhodamine, 
were employed and their penetration from the CLs, DLs and SLNs followed. The IPHSF 
model offers the advantage of working with the skin in the presence of dermal circulation, 
thus mimicking the in vivo human conditions to a higher extent. The confocal laser scanner 
microscopy (CLSM) technique was used to follow the penetration profiles. Moreover, a 
comparison of the marker penetration on IPHSF model with some of the established skin 
penetration models such as cellophane membrane and full thickness pig/human full thickness 
skin in the Franz diffusion cells system was performed.  
 
2. Materials and methods 
2.1. Materials 
Lipoid S 100 (phosphatidylcholine from soybean, >94% pure; PC) was a gift from Lipoid 
GmbH (Ludwigshafen, Germany). Calcein, rhodamine B, methanol CHROMASOLV®, 
magnesium sulfate heptahydrate, potassium chloride, sodium bicarbonate, sodium chloride, 
trichloroacetic acid (≥99.0%), Fiske-Subbarow reducer reagent, ammonium molybdate, 
phosphorus standard solution, sodium deoxycholate (SDCh) and Triton™ X-100 were 
purchased from Sigma-Aldrich Chemie (Steinheim, Germany). Potassium dihydrogen 
phosphate, glucose, hydrogen peroxide (30%) and calcium chloride were obtained from 
Merck KGaA (Darmstadt, Germany). Propylene glycol (PG) was purchased from NMD – 
Norwegian Medical Depot AS (Oslo, Norway), Albunorm® (human serum albumin, 200 
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mg/mL) from Octapharma AG (Lachen, Switzerland) and sucrose from VWR International 
bvba/sprl (Leuven, Belgium). Sulfuric acid was purchased from May and Baker LTD 
(Dagenham, UK). Cellophane membrane was obtained from Max Bringmann KG 
(Wendelstein, Germany) and pig ears from Nortura AS (Bardufoss, Norway).  
 
2.2. Preparation of liposomes 
CLs and DLs with calcein or rhodamine were prepared by the film hydration method [21].  
PC (300 mg) for CLs or PC/SDCh (total 300 mg; 85/15 % as weight ratio) for DLs were 
dissolved in approximately 20 mL of methanol in a round bottomed flask. When applicable, 
rhodamine (47.9 mg) was dissolved together with the lipid in organic solvent resulting in 10 
mM rhodamine solution. The organic solvent was completely removed under a vacuum (50 
mbar) using a rotary vacuum evaporator (Büchi Rotavapor R-124 with Büchi Vacuum Pump 
V-700, Büchi Labortechnik AG, Flawil, Switzerland) for 1 h at 45 ºC. The resulting lipid film 
was then rehydrated in 10 mL of modified Krebs-Henseleit buffer (KHb) (pH 7.40; 280 
mOsm; 110 mM NaCl, 3.8 mM KCl, 1.4 mM KH2PO4, 1.2 mM MgSO4, 31 mM NaHCO3, 
2.5 mM CaCl2, 11 mM glucose and 10 mM sucrose) by hand shaking at room temperature 
(23-24 ºC) for 20 min. For calcein-containing liposomes, calcein (62.2 mg) was dissolved in 
the KHb to form 10 mM calcein solution used to rehydrate the film. All liposomal 
suspensions were stored overnight in the fridge (+4 ºC) prior to the characterisation.  
 
2.3. Preparation of solid lipid nanoparticles 
SLNs with calcein or rhodamine were prepared by the solvent injection method [22] with 
some modifications. PC (1.20 g) was dissolved in methanol. The obtained lipid solution (120 
mg/mL; 2 mL) was then rapidly injected via an injection needle (Sterican® 0.30 x 12 mm, 
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Braun Melsungen AG, Melsungen, Malaysia) into KHb solution (6 mL) under the stirring 
(300 rpm). For SLNs containing calcein, the marker was dissolved in the KHb solution used 
to prepare nanoparticles, whereas for SLNs containing rhodamine, the lipophilic marker was 
dissolved in the lipid solution. Both markers were applied in the same concentrations as used 
for CLs and DLs preparation. The suspension was stirred for 2 h at room temperature (23-24 
ºC) and kept overnight in the fridge (+4 ºC) prior to the characterisation.  
 
2.4. Size reduction  
The original size of CLs, DLs and SLNs containing either calcein or rhodamine was reduced 
by the hand extrusion through the polycarbonate membrane (Nuclepore® Track-Etched 
Membranes, Whatman House, Maidstone, UK). The pore size of the membranes and the 
number of extrusion cycles were adjusted for each formulation to obtain vesicles within the 
size range of 200-300 nm. CLs, DLs and SLNs containing calcein were extruded stepwise 
through the 0.8, 0.4 and 0.2 µm pore size membranes, three times for each pore size. The 
same was done for CLs containing rhodamine, while DLs containing rhodamine were 
extruded two times through the 1.2 µm pore size membrane. SLNs containing rhodamine 
were extruded stepwise through 0.8 and 0.4 µm pore size membranes (three times each) and 
two times through 0.2 µm pore size membranes. All extruded CLs, DLs and SLNs were then 
kept in the fridge (+4 ºC) for a minimum of 3 h prior to characterisation and usage. 
  
2.5. Size measurements 
The particle size distributions of all CL, DL and SLN suspensions were determined by the 
dynamic light scattering [23] (NICOMP Submicron Particle Sizer Model 370; NICOMP 
Particle Sizing system, Santa Barbara, California, USA). The sample preparation was 
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performed in a laminar flow bench. Firstly, the test tubes were flushed once with KHb 
previously filtrated through 0.2 µm syringe filter (Bulk Acrodisc® 25 mm Syringe Filter, Pall 
Life Sciences, East Hills, New York, USA). The samples were diluted with the KHb to obtain 
a particle intensity between 250-350 kHz. The analyses were run in a vesicle mode for CLs 
and DLs, and solid particle mode for SLNs, respectively. Each measurement was done in 
triplicates (runtime of 10 min; 23-24 ºC). The size distributions of all nanocarriers, expressed 
as the mean diameter and polydispersity index (PI), were determined using the intensity-
weighted distribution. 
       
2.6. Zeta potential measurements 
The zeta potential of liposomal and solid lipid nanoparticles suspensions was determined on 
Malvern Zetasizer Nano – ZS (Malvern, Oxford, UK) [24]. The instrument was calibrated 
with Malvern Zeta potential transfer standard (-42 ± 4.2 mV). A folded capillary cell 
(DTS1060) was used for the measurements. The cell was rinsed with ethanol and then with 
filtered water (0.2 µm syringe filter) prior to the sample. Each sample was diluted in a 
filtrated water (1:10 and 1:20 volume ratio for calcein- and rhodamine-containing 
nanocarriers, respectively) to achieve a suitable count rate. The diluted sample was injected 
into the folded capillary cell, assuring that no air bubbles formed during the injection. All 
measurements were performed at 25 ºC with an equilibration time of 180 sec. Three 
measurement runs were performed for each sample, assuring an attenuator of 6-7. 
      
2.7. Entrapment efficiency determination 
The unentrapped calcein was separated from the extruded CLs, DLs and SLNs by dialysis. 
Typically, 5 mL of suspension were placed in a dialysis bag (Mw cut off 12,000-14,000 Da, 
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Medicell International Ltd, London, UK) and dialysed against 500 mL of KHb for 6 h at room 
temperature. The dialysis bag was immersed in fresh KHb (500 mL) and dialysis continued 
for additional 3 h. The volume of the receptor medium was chosen to assure the sink 
conditions. After the dialysis, CLs, DLs and SLNs were mixed with a Triton solution (5%, 
v/v) to dissolve the lipids before quantification of calcein by measuring fluorescence on a 
Polarstar fluorimeter (Fluostar; BMG Technologies, Offenburg, Germany) with excitation and 
emission wavelengths at 485 and 520 nm, respectively. Standard curves of calcein in KHb 
solution and calcein in Triton solution (5%, v/v) were used to determine the unentrapped and 
entrapped calcein, respectively. A concentration range between 0.12 and 1.37 µg/mL was 
used for both the standard curves (R2 of minimum 0.9990). A blank consisting of KHb or 
Triton solution (5%, v/v) was subtracted from the fluorescence values.  
Ultracentrifugation was performed to separate unentrapped rhodamine from CLs and SLNs, 
while gentle centrifugation was used for DLs. Extruded CLs and SLNs were centrifuged 
(Beckam model L8-70M ultracentrifuge with an SW 60 Ti rotor, Beckam Instruments, Palo 
Alto, California, USA) at 110,000 g for 1 h at 10 ºC. Extruded DLs were centrifuged (Biofuge 
stratos centrifuge with a swinging bucket rotor 4x 180 mL; Heraeus instruments GmbH, 
Hanau, Germany), at 3,000 g for 25 min at 10 ºC. The supernatants were separated from the 
pellets, which were resuspended in KHb. Lipids in both supernatants and pellets were 
dissolved in methanol and the rhodamine content was determined fluorometrically on a 
Polarstar fluorimeter (Fluostar; BMG Technologies, Offenburg, Germany) with excitation and 
emission wavelengths at 544 and 590 nm, respectively. To avoid evaporation of methanol 
during the fluorescence measurements, all samples were diluted in KHb to obtain a methanol 
concentration of 50% (v/v). The standard curve of rhodamine in methanol/KHb solution (1:1, 
v/v) was prepared using the concentrations ranging from 0.10 to 1.20 µg/mL (R2 of minimum 
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0.9980). A blank consisting of methanol/KHb solution was subtracted from the fluorescence 
values. 
The recovery of calcein and rhodamine was determined and found to be between 100.3 and 
107.7%, respectively. 
 
2.8. Phospholipid content 
The phospholipid content in CLs, DLs and SLNs was determined to enable calculation of 
entrapment efficiency expressed as the marker/lipid ratio. A modification of Bartlett method 
was used [25]. In brief, all samples were diluted in distilled water (typically 1:200, v/v). An 
aliquot of diluted sample (1 mL) was mixed with sulfuric acid (5 M; 0.5 mL) and then 
incubated at 160 ºC for a minimum of 3 h. After the cooling, two drops of hydrogen peroxide 
30% were added and the solutions incubated at 160 ºC for 1.5 h. After the cooling, 
ammonium molybdate (0.22%, w/v; 4.6 mL) and Fiske-Subbarow reducer (0.2 mL) were 
added, vortexed and incubated at 100 ºC for 7 min. The samples were then cooled down and 
analysed by UV UV-VIS spectrophotometry at 830 nm using a SpectraMax 190 Microplate 
Reader (Molecular Devices, California, USA)The standard curve was prepared using a 
phosphorus standard solution in a concentration range of 1-8 µg/mL (R2 of minimum 0.9990).   
 
2.9. Skin penetration experiments on IPHSF model 
The skin penetration of calcein and rhodamine from CLs, DLs and SLNs was evaluated on the 
recently established IPHSF model [20]. The human skin flaps (the mean age of 49.3 years, 
range 26-72 years) were obtained from the abdominoplasty operations of female patients, 
after receiving their written consent prior to the surgery. The excess of skin and subcutaneous 
fatty tissue as residue after the surgery are normally disposed, therefore no ethical approval by 
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the Norwegian Ethical Committee was required. However, all experiments were performed in 
accordance with the Declaration of Helsinki Principles. Each formulation (CLs, DLs and 
SLNs containing either calcein or rhodamine) was tested in triplicates on three independent 
human skin flaps, obtained from different female donors. Human serum albumin (final 
concentration of 30 mg/mL) was included in the KHb to prepare the perfusate solution. The 
human skin flaps were cannulated and perfused with the perfusate within 90 min after their 
excision. The temperature of the perfusate entering the flap (inlet temperature) was 
maintained at approximately 32 ºC using a heating circulator set at 38 ºC. The use of an 
infrared (IR) camera (FLIR ONE, Thermal Imaging Camera for iOS; FLIR Systems) allowed 
the selection of the best perfused skin diffusion area (49 cm2) having a skin temperature of ca. 
32 ºC. The formulation (7 mL) was applied onto the selected perfused skin diffusion area 
using an adhesive patch as described by Ternullo and colleagues [20]. The experiments were 
carried out for 6 h and sampling was performed by collecting the perfusate every hour, 
assuring the sink conditions throughout the experiment. The physiological parameters, namely 
the perfusion inlet pressure, perfusion flow rate and inlet temperature, were recorded 
throughout the experiments [20]. To exclude oedema formation, the weight and thickness of 
each flap were measured before and at the end of the experiment. A weight and thickness 
variations of less than 10% was found acceptable. Blood cells were removed from the 
collected perfusate by the centrifugation (1914 g, 20 min), while plasma proteins were 
precipitated using trichloroacetic acid (58.82%, w/v) [20]. The obtained samples were then 
analysed fluorometrically, as described above, to quantify the penetrated markers through the 
full thickness IPHSF. Moreover, the amount of the markers retained onto the skin flap surface 
was determined fluorometrically.   
 
2.9.1. Confocal laser scanning microscopy on IPHSF model 
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To localise the two markers in the IPHSF model after the skin penetration experiments, 
CLSM technique was employed [20] (Leica TCS SP5 microscope equipped with an Argon 
laser; Leica Microsystems CMS GmbH, Mannheim, Germany). Briefly, the imprint technique 
was used to prepare the samples. At the end of the skin penetration experiments, the treated 
perfused skin flap area was cut cross-sectionally and attached onto a microscope slide. 
Formalin (SPRAYFIX®, Histolab Products AB, Gothenburg, Sweden) was sprayed to fix the 
cells that remained on the slide. Laser lines of 488 and 568 nm were used to excite calcein and 
rhodamine, respectively. A spectral range of 500-550 nm and 570-610 nm were used to detect 
the calcein and rhodamine fluorescence, respectively.   
 
2.10. In vitro skin penetration experiments 
Franz diffusion cells (PermeGear, Bethlehem, USA) were used to perform in vitro skin 
penetration experiments following the method reported earlier [20]. Cells of 1.77 cm2 
diffusion area with a receptor volume of 12 mL were used. Cellophane membrane was pre-
soaked in KHb for 30 min prior to the experiment. KHb constituted the receptor phase, which 
was maintained at 37 ºC throughout the experiment to assure the physiological skin 
temperature of 32 ºC. CLs, DLs and SLNs containing either calcein or rhodamine were added 
to the donor chamber (sample volume of 600 µL). As controls, calcein in KHb and rhodamine 
in KHb/PG (0.5%, v/v) were used. The content of the two markers in the tested samples was 
determined fluorometrically prior to the penetration study and the concentration of markers in 
the donor chamber was equalised in all samples to assure the same concentration gradient. 
Sampling from the receptor chamber was done every hour for a period of 8 h. The withdrawn 
samples (500 µL) were replaced by an equal volume of fresh KHb to assure the sink 
conditions. All experiments were performed in triplicates. The markers penetrated through the 
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cellophane membrane and non-penetrated markers were quantified fluorometrically as 
described in section 2.7. 
 
2.11. Ex vivo skin penetration experiments 
Full thickness pig and human skin were used for ex vivo skin penetration studies [20]. Frozen 
pig ear skin slices were thawed, rinsed with water and cleared from the subcutaneous fat. 
Human skin was obtained from the resected skin during abdominoplasty of female patients, 
after their written consent was received. No ethical approval for the use of human skin was 
required by the Norwegian Ethical Committee, since the excess of skin panni is normally 
disposed after the surgery. The experiments were conducted in accordance with the 
Declaration of Helsinki Principles. The excised portion of human skin was rinsed with water 
and, after a removal of the subcutaneous fat, stored at -20 ºC and thawed 30 min before the 
start of the experiment. Each formulation and controls were tested in triplicates on human skin 
that was obtained from the same patient. Pig and human skin thicknesses were measured prior 
to the experiment and skin with thickness of approximately 1.50 mm was used. The skin was 
mounted into the same Franz diffusion cells used for the in vitro experiments; the SC side was 
facing the donor chamber. The tested formulations, receptor medium and sampling time were 
the same as in the in vitro skin penetration experiments (section 2.10). The markers 
Ppenetrated through the full thickness pig/human skin and non-penetrated markers were 
quantified as described in section 2.7. 
 
2.12. Statistical analyses 
The student's t-test (paired) was used to determine a statistical significance. A p value of less 




3. Results and discussion 
Improved drug delivery to deeper skin layers could enable improved drug outcome in many 
topical therapies reducing the need for systemic treatment. However, the complex barrier of 
the skin, particularly the SC, which is the barrier responsible for rate-limiting step in skin drug 
penetration, should be addressed when designing/developing the dermal formulations [26]. 
Phospholipid-based nanocarriers have shown ability to enhance drug penetration through the 
SC and allow the sustained and controlled release of associated drugs [27-29]. The changes in 
the composition of phospholipid-based nanocarriers affect their interaction with the skin [14]. 
Therefore, a direct comparison of the skin penetration enhancement by the different 
phospholipid-based nanocarriers is helpful in the optimisation of efficient 
nanopharmaceuticals destined for localized skin therapy. The right choice of the nanocarrier 
would lead to the optimal therapeutic drug levels in the specific skin layers, and could be 
tailored for the specific skin disease.  
 
3.1. Characteristics of the phospholipid-based nanosystems 
Table 1 presents the characteristics of phospholipid-based nanosystems used in this study. The 
optimal size of nanocarriers for dermal drug delivery was proposed to be 200-300 nm [30]. 
The size of liposomes and solid lipid nanoparticles containing either calcein or rhodamine was 
between 200 and 300 nm, as targeted. The extrusion as a method for a vesicle/particle size 
reduction has shown to be a suitable method to obtain the desired vesicle/particle size and 
rather homogenous systems. The PI was found to be lower than 0.3 for all vesicles/particles 
(between 0.06 and 0.27) indicating relative homogeneity in size. Among the nanocarriers 
containing calcein, a significant difference (p < 0.05) in the size was observed for DLs, which 
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were smaller (201 nm) as compared to both CLs (265 nm) and SLNs (220 nm), respectively. 
Our finding is in accordance with literature [31-33]. The presence of SDCh in the 
phospholipid bilayers of DLs provides elasticity and flexibility to the liposomes, and reduces 
their surface tension. Rather homogenous size (PI < 0.3) was also obtained for rhodamine-
containing nanocarriers. CLs and SLNs were of similar mean size (244 and 227 nm, 
respectively); a bimodal size distribution (Nicomp distribution) was observed for SLNs where 
a small percentage (6.5%) of smaller particles (24 nm) was found. DLs containing rhodamine  
were characterised by a bimodal size distribution (Table 1) as observed for SLNs. The main 
peak within the size distribution of DLs was higher (294 nm) compared to both CLs and 
SLNs; the of mean size of 294 nm exhibiting also the highest PI (0.27) was also the highest as 
compared to the other formulations. This size was obtained after only two cycles of extrusion 
through the polycarbonate membrane with 1.2 µm pore size membranes. Considering a 
potential pilot scale manufacturing, this could be considered an advantage regarding the 
manufacturing. 
The surface charge of nanocarriers is also a factor that can play an important role in the skin 
penetration of associated drugs [34]. Our phospholipid-based nanosystems exhibited zeta 
potential in accordance with the nature of the material used for their preparation. CLs and 
SLNs containing either calcein or rhodamine had a zeta potential close to neutral, due to the 
main presence of neutral PC. DLs containing either calcein or rhodamine beard a strong 
negative surface charge, providing them with additional stability [21]. Although the skin has a 
net negative charge, negatively charged liposomes have shown to enhance skin drug 
penetration [34].  
To assure improved skin deposition of nanocarrier-associated drugs, it is crucial to assure 
high drug load. In this study, we have used two different markers as model substances for a 
hydrophilic and a lipophilic drugs, respectively. The entrapment efficiencies for nanocarriers 
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containing calcein, expressed as a marker/lipid ratio, were not significantly different. 
Unexpectedly, DLs entrapped more calcein compared to CLs, although DLs were smaller. 
The presence of SDCh may increase the incorporation of this marker in DLs [35]. We 
expected a lower entrapment efficiency for SLNs, since they are known to possess low 
loading capacity for hydrophilic compounds [36]. However, Suter and collaborators [37] have 
recently demonstrated that SLNs might also incorporate high load of hydrophilic compounds, 
such as peptides, which is in agreement with our results. CLs containing rhodamine 
incorporated the highest amount of the marker compared to both DLs and SLNs (Table 1). 
The presence of SDCh in DLs decreased the entrapment efficiency, possibly due to a 
competition between rhodamine and SDCh both accommodated in the phospholipid bilayer of 
liposomes [31]. It is known that the lipids in SLN can re-crystallize into a highly ordered 
crystalline structure. This process can cause drug expulsion, reducing the entrapment 
efficiency [38]. Our results are in accordance with literature [39].  
 
3.2 Penetration enhancing effect of the phospholipid-based nanocarriers in the IPHSF model 
Optimisation of effective nanosystems for skin therapy requires validated skin penetration 
models. The recently established drug penetration (IPHSF) model was used for this purpose. 
The model offers the possibility of working with the presence of dermal circulation in the 
conditions similar to the in vivo, important parameter in the penetration studies [40]. The use 
of an IR camera allowed visualisation of the perfused skin flap area destined for the topical 
application of the tested formulations on the IPHSF model and served as a validation module 
of the model. IR images of the representative flaps taken during the experiments are shown in 
Fig. S1. The skin area, where the formulations were applied, was perfused throughout the 
whole penetration experiment. The physiological parameters were monitored during the 
experiment. The perfusion inlet pressure, flow and inlet temperature were adjusted to 
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maintain the perfusion of the human skin flaps (skin surface temperature of ca. 32 ºC). 
Physiological parameters recorded during the skin penetration experiments in the IPHSF 
model are shown in Fig. S2. Although the perfusion inlet pressures varied, the flap perfusion 
was assured throughout the experiments and the variation of weight and thickness of flaps 
was found to be less than 10% (data not included). The lower perfusion inlet pressures did not 
affect the perfusion and the higher pressures did not cause oedema formation, which was 
found acceptable. The temperature remained constant throughout the experiments.  
No markers were found in the perfusate, indicating that our nanocarriers were not able to 
deliver the two markers deeper into the dermis layer allowing them to become absorbed in the 
systemic circulation. Therefore, all the investigated nanocarriers can be be used as drug 
delivery systems for dermal, rather than transdermal drug therapy. This was expected 
considering their size. However, the limited time (6 h) of the experiment should be 
considered. Whether a longer time would permit some of the nanocarriers to penetrate deep 
enough into the dermis to enable marker absorption remain to be addressed in in vivo 
experiments. Our results are in accordance with Chen and colleagues [19], although their 
studies were performed using human skin in the Franz diffusion cells. No permeation of the 
tested markers through the full thickness human skin was observed in finite dose application 
for all tested nanocarriers and only low percentages (0.001%) of the hydrophilic marker were 
detected in the receptor fluid when the formulations were applied in infinite dose [19]. The 
perfusion of the IPHSF could not be assured over a longer time (more than 6 hours), and we 
assumed that the perfused skin should permit penetration through the full thickness skin 
barrier at faster rate than the non-living skin. Assessment of the penetration potential of three 
types of nanocarriers containing either calcein or rhodamine was also evaluated by the amount 
of the marker retained on the top of the skin at the end of skin penetration experiments. Fig. 1 
presents the percentages of the non-penetrated markers, indicating the markers retained on the 
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top of skin surface of the IPHSF. The rank order of the tested nanocarriers according to their 
capability to enhance the penetration of the two markers through the SC was CLs < DLs ≈ 
SLNs. DLs are expected to be more effective than CLs in drug transport across the skin [41]. 
Regarding SLNs, our results are in accordance with literature [27]. Clares and colleagues [27] 
did not find a significant difference in the permeation of retinyl palmitate from CLs and SLNs 
(4.36 and 3.64 µg, respectively) through human skin. However, SLNs were found to be more 
effective in enhancing the penetration into the upper SC, similar to our findings.  
To assure that our assumption on the penetration within the SC was correct and visualise the 
differences between the investigated nanocarriers, a CLSM study was performed. The 
obtained confocal images (Fig. 2 and 3) supported our findings on the skin penetration 
profiles through the IPHSF model. Compared to the control (untreated human skin flap), 
fluorescence was detected in all skin samples, indicating a presence of marker. The delivery 
of the two markers into/through the skin layers was, however, dependent on the investigated 
nanocarriers. Calcein distribution through the IPHSF was found more uniform throughout the 
whole skin flaps treated with DLs (Fig. 2C) compared to CLs (Fig. 2B). This confirmed the 
better ability of DLs to enhance the skin penetration of the marker deeper through/into the 
skin layers. Earlier CLSM studies comparing skin-penetration depth of the hydrophilic marker 
fluorescein sodium from CLs and DLs showed stronger fluorescence and deeper penetration 
in the skin samples treated with DLs compared to CLs [42]. Although the authors performed 
the penetration study using the pig skin, the same results as obtained in our model were 
reported. Calcein from SLNs was found in the deeper skin layers (Fig. 2D) as compared to 
CLs-associated calcein. This indicates and confirms the ability of SLNs to enhance the 
penetration of calcein as a hydrophilic model substance through the SC. For rhodamine, the 
strongest fluorescence was found in SC and was not depend on the type of vesicles, in 
agreement with literature [19]. The weakest fluorescence was detected in the IPHSF treated 
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with the rhodamine-containing CLs (Fig. 3B), while the strongest was detected in the flaps 
treated with SLNs (Fig. 3D). DLs and SLNs assured higher penetration of rhodamine 
through/into the skin layers (Fig. 3C and 3D) compared to CLs. These results might be 
explained in part by the negatively charged surface of DLs; accumulation within the skin has 
shown to be more pronounced for negatively charged liposomes [14]. The enhanced 
penetration of lipophilic compounds from SLNs through the SC is also in agreement with 
literature [43,44].  
The depth of the skin penetration of the two markers was clearly affected by the type of lipid-
based nanocarriers the markers were associated with. The different composition of the 
nanocarriers plays a crucial role in determining their mechanism of action. CLs made of PC 
possess certain similarities with the SC lipids, which allow the fusion of the vesicles with the 
SC lipids, causing changes in the structure of the intercellular SC lipids. Therefore, CLs can 
act as penetration enhancers by loosening the lipid structure of the SC and lowering the 
permeability barrier of the skin. CLs can collapse onto the skin due to their fusion/mixing 
with the SC lipids, leading to the formation of an additional barrier and limiting the 
penetration of the incorporated drug to a higher extent [11].      
When SDCh is incorporated in liposomes to form DLs, the skin penetration enhancing effect 
appears to be stronger. The presence of an edge activator in the lipid bilayer determines 
flexibility of the DLs and allows them to potentially squeeze into the corneocytes in the SC, 
thus delivering the drug deeper into the skin layers. Therefore, DLs appear to enhance drug 
penetration due to a synergistic effect between their deformability and their action as 
penetration enhancers. The deformability of DLs is also composition dependent. El Zaafarany 
and collaborators [28] have shown that the optimal deformability of DLs is reached when the 
ratio of phosphatidylcholine:edge activator is 85:15%, the same as used in our study. This 
further explains the capability of DLs in enhancing drug penetration into the skin compared to 
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CLs [28]. As discussed earlier, the surface charge of nanocarriers plays a role in the skin 
penetration of drugs. Our DLs were negatively charged and it has been shown that a negative 
vesicle surface charge increases drug skin penetration [14].  
Regarding SLNs, two mechanisms of skin penetration enhancement are proposed; SLNs can 
adhere and fuse with the SC lipid [43] or they can form an occlusive film onto the skin 
surface preventing transepidermal water loss [29; 45]. The penetration enhancement of SLNs 
is dependent on the physicochemical properties of the encapsulated drug and the lipids. A 
stronger fluorescence observed for rhodamine as compared to calcein indicates that SLNs 
assured higher penetration of rhodamine through/into the skin layers (Fig. 3). This might be 
explained by the lipophilicity of the drugs, which affects the drug-particle interactions, the 
distribution of the drug within the SLNs and consequently the drug delivery by SLNs [46]. 
Küchler and collaborators performed electron spin resonance spectroscopy studies on SLNs 
using the spin probes with different lipophilicities. The authors showed that lipophilic probes 
were attached to the particles lipid surface, while hydrophilic probe was located in the layer of 
the surfactant. These distributions in the SLNs affected the skin penetration: the lipophilic 
probe penetrated faster and in a higher extent compared to the hydrophilic one [46], in 
agreement with our results. Similar studies have been performed by Saeidpour and 
collaborators [47], regarding the distribution of a lipophilic drug, dexamethasone, in SLNs. 
The authors found that the drug is located in the outer shell of the SLNs when immersed in 
aqueous solution but it can be easily released from the nanoparticles, which is in accordance 
to our results on rhodamine-containing SLNs (Fig. 3D).  
When describing the skin penetration process of drugs, the interaction between the 
nanocarrier and the skin is not the only factor that has to be taken into account. The 
partitioning of the drug from the nanocarrier to the skin also plays a role in the skin 
penetration [19]. Comparing the penetration of calcein and rhodamine in the IPHSF model, 
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calcein was found to be more uniformly distributed throughout the skin layers (Fig. 2) 
compared to rhodamine (Fig.3), which was mainly accumulated in the SC. The percentage of 
non-penetrated calcein, a hydrophilic marker with a low logP (-5.02), was higher compared to 
rhodamine that has lipophilic properties and higher logP (1.95). The same behaviour was 
observed for all investigated nanosystems. The lipophilic rhodamine is mainly released from 
nanocarriers in the lipophilic environment provided by the SC [48], while the hydrophilic 
calcein is able to reach deeper into the hydrophilic dermal layer that is maintained perfused by 
KHb (hydrophilic medium) [20]. Therefore, dermal perfusion affected the skin penetration of 
the hydrophilic marker. Moreover, DLs and SLNs enhanced skin penetration of calcein to a 
higher extent compared to CLs, whereas the difference between DLs/SLNs and CLs was not 
observed for rhodamine (Fig. 1). This might be explained by the difference in lipophilicity of 
the two markers. For highly lipophilic compounds, such as rhodamine, the penetration 
enhancement by the nanocarriers is less evident because they possess the intrinsic capacity to 
move with relative ease through the SC. In the case of hydrophilic substances such as calcein, 
the nanocarriers have the opportunity to act as penetration enhancer due to the low partition 
coefficient of hydrophilic compounds [19].    
 
3.3 In vitro and ex vivo skin penetration  
All nanocarriers exhibited a sustained permeation of calcein through the cellophane 
membrane compared to the control (calcein in KHb solution) (Fig. 4A). Among the 
investigated nanocarriers, the highest calcein permeation was observed from CLs. DLs are 
known to increase the penetration of incorporated drugs due to their elasticity [31]. We did 
not observe this typical mechanism of action for DLs in our in vitro studies. A possible 
explanation might be due to their net negative surface charge (-32 mV), which is similar to the 
charge of cellophane membranes [49]. Since both surfaces have negative zeta potentials, the 
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energy barrier might prevent DLs deposition on the cellophane membrane, interfering with 
calcein penetration through the barrier. SLNs permitted the lowest calcein penetration of 
calcein through the barrier, in agreement with reported studies on SLNs incorporating 
hydrophilic compounds [38,50].  
Rhodamine permeation profiles from all nanocarriers through the cellophane membrane are 
presented in Fig. 4B. Both CLs and SLNs were able to sustain the permeation of rhodamine, 
as expected for lipophilic compounds [27,29]. However, SLNs sustained rhodamine release to 
a higher extent compared to CLs. The presence of a solid lipid matrix in SLNs, in contrast 
with the fluid core of liposomes, reduces the mobility of the incorporated drugs. This might 
assure a more controlled release of the drug from the SLNs compare to CLs [51]. The highly 
ordered crystalline structure of the SLNs strongly accommodates the drug and slows the drug 
release [38]. DLs containing rhodamine exhibited the highest marker penetration through the 
barrier. Although a charge repulsion between the DLs and cellophane membrane might be 
relevant for the calcein penetration (Fig. 4A), for rhodamine the observed higher a higher 
release, compared to the other nanocarriers, might be contributed to the lipophilicity of the 
marker. Rhodamine is accommodated in the bilayer of DLs, while calcein is incorporated in 
the inner aqueous core. Therefore, rhodamine is more likely to be released from DLs even 
with a possible charge repulsion of DLs with the cellophane membrane.  
Skin permeation of calcein from nanocarriers through the full thickness pig skin is shown in 
Fig. 4C. The amount of penetrated calcein through the full thickness pig skin from all 
nanocarriers was lower compared to in vitro studies (cellophane membrane). A sustained 
release of calcein from all nanocarriers was obtained compared to the control. DLs assured 
higher calcein penetration through the full thickness pig skin compared to CLs and SLNs, as 
expected [42]. These results also confirmed that the lower calcein permeation from DLs 
observed in in vitro studies (Fig. 4A) might be due to charge repulsion between DLs and 
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cellophane membrane. Skin penetration of rhodamine from nanocarriers through the full 
thickness pig skin (Fig. 4D) showed similar trend as in in vitro studies as well as in literature 
[52]. However, no significant difference was observed among the nanocarriers and the 
penetration of rhodamine through the full thickness pig skin was lower from all nanocarriers 
compared to in vitro studies. Both markers, regardless of the nanocarrier types, were not 
found to permeate the full thickness human skin in the Franz diffusion cells system (data not 
shown). Therefore, the skin penetration through the full thickness human skin in the Franz 
diffusion system appears to closely resemble the penetration observed in our IPHSF model. 
This highlights the importance of using the human skin in the skin penetration studies. 
The amount of non-penetrated markers (retained on the top of the different skin membrane 
models) was quantified at the end of in vitro and ex vivo skin penetration experiments to 
compare the penetration determined on the IPHSF model with the established skin models. 
Fig. 5 represents a summary of the two markers penetration through the in vitro and ex vivo 
full thickness skin models. As discussed earlier, all nanocarriers exhibited lower penetration 
of calcein compared to the control both through the cellophane membrane and full thickness 
pig skin; while no calcein was detected in the receptor medium when full thickness human 
skin was tested in Franz diffusion cells system. Moreover, all nanocarriers were able to retain 
higher amount of calcein on the top of the skin in all tested skin models as compared to the 
control (Fig. 5A). Retention of calcein on the top of the human skin in the Franz diffusion 
cells system and IPHSF model were comparable, except for SLNs. SLNs mediated a lower 
retention of associated calcein on the IPHSF model compared to ex vivo human skin. This 
might be explained by the fact that the perfusion of human skin flap is performed with an 




Retention of rhodamine on the top of all skin models is shown in Fig. 5B. The non-penetrated 
amount of rhodamine was found to be lower compared to calcein, in agreement with data 
obtained from the IPHSF model. Our results indicate that rhodamine remained accumulated 
within the SC, due to its lipophilic nature. Among the investigated nanocarriers, CLs and 
SLNs assured higher retention of rhodamine on all the skin models, while DLs were able to 
enhance rhodamine penetration through the full thickness skin barriers. DLs containing 
rhodamine were earlier tested in the pig skin by Carrer and co-authors [53]. The authors found 
that negatively charged DLs, as our DLs, were able to increase a marker penetration through 
the pig skin to a greater extent. CLs and SLNs did create a drug reservoir in the skin [53]. 
Jensen and collaborators [29] tested the penetration properties of SLNs containing 
corticosteroids, lipophilic drugs, in the pig skin and compared SLNs with an ointment. The 
penetration of the drug through the intact skin was reduced when the drug was formulated in 
SLNs and a higher amount of drug remained in the upper layers of the skin [29], in agreement 
with our findings. DLs exhibited the lowest retention of rhodamine on the human skin in 
Franz diffusion cells compared to the other nanocarriers. This suggests that DLs improved the 
penetration of the marker through the human SC. Skin penetration studies and two-photon 
microscopy analysis from Simonsson and collaborators [54] support our findings. Although 
they tested rhodamine-containing ethosomes, they found an increased penetration of 
rhodamine from ethosomes compared to the hydroethanolic solution. Moreover, as we 
observed in the CLSM studies on the IPHSF model, they also observed a strong fluorescence 
from rhodamine in the SC when incorporated in ethosomes. Penetration of rhodamine from all 
nanocarriers through the IPHSF model was found to be more similar to the ex vivo human 
skin than through cellophane membrane and pig skin; the same trend as observed for calcein.  
Although the penetration profile observed for all nanocarriers incorporating either calcein or 
rhodamine through all the full thickness skin barrier models was the same, the retention of the 
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two markers on the top of cellophane membrane and pig skin differed significantly (p < 0.03) 
from the human skin and IPHSF model. The artificial membranes have already shown their 
limited ability to reflect the complex interactions between the human skin and the applied 
formulations, often resulting in non-comparable findings [55]. Although pig ear skin is more 
able to represent in vivo human skin than artificial membranes [56], recent studies have shown 
that frozen/thawed pig skin is more permeable than freshly excised skin. It has been 
postulated that the high ceramide and low cholesterol levels in pig skin might cause an easy 
disruption of the SC due to ice crystalline formation. This leads to impaired SC barrier and 
thus higher permeability of drugs [57]. Moreover, especially for pig skin, the total recovery of 
both markers was reported to be lower than the stated ideal value (100 ± 15%) [58]. Although 
we only quantified the markers penetrated through the full thickness skin barriers and non-
penetrated markers and did not extract any markers retained in the barriers, it might be 
hypothesised that the impaired SC barrier of frozen/thawed pig skin favours the retention of 
the markers, especially the lipophilic rhodamine, within the skin. Therefore, the low recovery 
might be explained by the non-considered amount of markers retained in the skin. Moreover, 
the markers penetrated through the full thickness skin barriers and non-penetrated amounts of 
both markers were calculated from the content of the two markers in the formulations 
determined fluorometrically prior to the penetration study. Therefore, another possible 
explanation for the low recovery might be an underestimation of the marker content, 
determined prior to the experiment, from the theoretical amount.  
The results indicate that it is crucial to test the nanocarriers on the reliable skin models able to 
mimic in vivo studies as close as possible and that the direct comparison of various 
nanocarriers can serve as an important step in development of the optimal dermal formulation 
targeting a specific dermal condition. It is necessary to note that the described nanocarriers 





This study confirmed the different skin penetration potential of three phospholipid-based 
nanocarriers using the IPHSF model, a model closely resembling the human studies. The 
differences in their lipid nanocarriers composition and surface charge determined their 
mechanism of action and a different skin penetration depth of the two markers. DLs and SLNs 
exhibited higher penetration of the two markers compared to CLs through the isolated 
perfused human skin flap model. Moreover, DLs and SLNs delivered both markers deeper 
into the skin layers compared to CLs. This comparative study could serve in the optimisation 
of phospholipid-based nanosystems for localized skin therapy and assist in the right selection 
of the nanocarrier for targeted drug delivery into the specific skin layers, depending on the 
targeted skin condition/disease. 
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Figures and figure legends: 
Fig. 1. Skin penetration of calcein and rhodamine from phospholipid-based nanocarriers 
(CL, DL, SLN) through the IPHSF model.  
The penetrated amount (marker in perfusate) was below detectable level in all skin 
penetration experiments (6 h). The non-penetrated markers were quantified after 6 h 
experiments. Results are presented as mean ± SD (n = 3).  
 
Fig. 2. Representative CLSM images of calcein-in-nanocarriers in IPHSF after 6 h of 
skin penetration experiments.  
The IPHSF was cross-sectionally cut, starting from the skin surface (upper side) to the 
subcutaneous fatty tissue (lower side). (A) Control, untreated IPHSF. (B), (C) and (D) IPHSF 
treated with calcein-containing CLs, DLs and SLNs, respectively.  
 
Fig. 3. Representative CLSM images of rhodamine-in-nanocarriers in IPHSF after 6 h 
of skin penetration experiments.  
The IPHSF was cross-sectionally cut, starting from the skin surface (upper side) to the 
subcutaneous fatty tissue (lower side). (A) Control, untreated IPHSF. (B), (C) and (D) IPHSF 
treated with rhodamine-containing CLs, DLs and SLNs, respectively. 
 
Fig. 4. Penetration profiles of calcein (left column) and rhodamine (right column) from 
CLs, DLs and SLNs through the cellophane membrane (A, B) and full thickness pig skin 
(C, D) using the Franz diffusion cells.  
As control, calcein in KHb and rhodamine in KHb/PG (0.5%, v/v) were used. The 
concentration of markers was equalised in all tested formulations to assure the same 
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concentration gradient. The skin penetration experiments were carried out for a period of 8 h 
and results are presented as the mean ± SD (n = 3). *p < 0.05.   
 
Fig. 5. In vitro and skin penetration studies (8 h) of calcein (A) and rhodamine (B) from 
CLs, DLs and SLNs through the cellophane membrane, full thickness pig skin and 
human skin using the Franz diffusion cells (n = 3).  
As control, calcein in KHb and rhodamine in KHb/PG (0.5%, v/v) were used. Calcein and 
rhodamine concentrations were equalised in all tested formulations to assure the same 
concentration gradient.  
 
 
Tables and table legends: 
Table 1. Characteristics of phospholipid-based nanocarriers containing calcein or 
rhodamine (n = 3 ± SD). 
a The diameter is expressed as the peaks in size distributions (nm) and weight intensity of 
each peak (%), which is indicated in parentheses  
b Polydispersity index  
c p < 0.05 





Supplementary material and Supp. Figures legends: 
Fig. S1. IR images of the representative human skin flaps taken during 6 h of skin 
penetration experiments.  
(A) IR images recorded before application of the formulations. (B), (C) and (D) IR images 
recorded at time 0, 3 and 6 h after the application of the formulations, respectively. A 
perfused skin area (skin temperature at ca. 32 ºC) was assured throughout the experiment. 
 
Fig. S2. Physiological parameters recorded throughout the skin penetration experiments 
(6 h).  
Values are presented as the mean ± SD (n = 3). 
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Fig. 5. In vitro and skin penetration studies (8 h) of calcein (A) and rhodamine (B) from CLs, DLs 
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